Market Access Views & Analysis

Views & Analysis

Market Access

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.

Market Access

Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.

Market Access

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Market Access

The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.

Market Access

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.